Palliative effects of an incomplete cytoreduction combined with perioperative intraperitoneal chemotherapy

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 33, Issue 6, 2010, Pages 568-571

  Chua, Terence C ^a   Baker, Bilal ^a   Yan, Tristan D ^a   Zhao, Jing ^a   Morris, David L ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Cytoreductive surgery; Hyperthermic intraperitoneal chemotherapy; Palliation; Peritoneal carcinomatosis; Symptoms

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; FLUOROURACIL; MITOMYCIN C;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CLINICAL ARTICLE; COLORECTAL CANCER; CYTOREDUCTIVE SURGERY; FEMALE; FOLLOW UP; GASTROINTESTINAL CARCINOMA; HUMAN; HYPERTHERMIC THERAPY; MALE; MORBIDITY; PALLIATIVE THERAPY; PERIOPERATIVE PERIOD; PERITONEUM MESOTHELIOMA; PERITONEUM PSEUDOMYXOMA; POSTOPERATIVE PERIOD; PROGNOSIS;

ANTINEOPLASTIC AGENTS; CARCINOMA; COHORT STUDIES; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, PARENTERAL; KAPLAN-MEIER ESTIMATE; LAPAROTOMY; MALE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PALLIATIVE CARE; PERIOPERATIVE CARE; PERITONEAL NEOPLASMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 78650008713     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181b9cf47     Document Type: Article

References (24)

1. Sugarbaker PH. Colorectal carcinomatosis: A new oncologic frontier. Curr Opin Oncol. 2005;17:397-399.
2. Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol. 2006;7:69-76.
3. Sugarbaker PH, ed. Peritoneal Carcinomatosis: Principles of Management. Boston, MA: Kluwer Academic Publishers; 1996.
4. Spratt JS, Edwards M, Kubota LT, et al. In: Spratt JS, ed. Peritoneal Carcinomatosis: Anatomy, Physiology, Diagnosis and Management. Chicago, IL: Year Book Publishers; 1986.
5. Smeenk RM, Verwaal VJ, Antonini N, et al. Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg. 2007;245:104-109.
6. Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: A multi-institutional study. J Clin Oncol. 2004;22:3284-3292.
7. Yan TD, Brun EA, Cerruto CA, et al. Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma. Ann Surg Oncol. 2007;14:41-49.
8. Elias D, Goere D, Blot F, et al. Optimization of hyperthermic intraperitoneal chemotherapy with oxaliplatin plus irinotecan at 43 degrees C after compete cytoreductive surgery: mortality and morbidity in 106 consecutive patients. Ann Surg Oncol. 2007;14:1818-1824.
9. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of The Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655.
10. Jacquet P, Sugarbaker PH. Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res. 1996;15:49-58.
11. Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221:29-42.
12. Jayne DG, Fook S, Loi C, et al. Peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2002;89:1545-1550.
13. Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88:358-363.
14. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
15. Grothey A, Sugrue MM, Purdie DM, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol. 2008;26:5326-5334.
16. Machida N, Yoshino T, Boku N, et al. Impact of baseline sum of longest diameter in target lesions by RECIST on survival of patients with metastatic colorectal cancer. Jpn J Clin Oncol. 2008;38:689-694.
17. Ronnett BM, Yan H, Kurman RJ, et al. Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis. Cancer. 2001;92:85-91.
18. Gough DB, Donohue JH, Schutt AJ, et al. Pseudomyxoma peritonei: longterm patient survival with an aggressive regional approach. Ann Surg. 1994;219:112-119.
19. Miner TJ, Shia J, Jaques DP, et al. Long-term survival following treatment of pseudomyxoma peritonei: An analysis of surgical therapy. Ann Surg. 2005; 241:300-308.
20. Glehen O, Mohamed F, Sugarbaker PH. Incomplete cytoreduction in 174 patients with peritoneal carcinomatosis from appendiceal malignancy. Ann Surg. 2004;240:278-285.
21. McQuellon RP, Danhauer SC, Russell GB, et al. Monitoring health outcomes following cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol. 2007;14:1105-1113.
22. Patriti A, Cavazzoni E, Graziosi L, et al. Successful palliation of malignant ascites from peritoneal mesothelioma by laparoscopic intraperitoneal hyperthermic chemotherapy. Surg Laparosc Endosc Percutan Tech. 2008;18:426-428.
23. Facchiano E, Scaringi S, Kianmanesh R, et al. Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of malignant ascites secondary to unresectable peritoneal carcinomatosis from advanced gastric cancer. Eur J Surg Oncol. 2008;34:154-158.
24. Garofalo A, Valle M, Garcia J, et al. Laparoscopic intraperitoneal hyperthermic chemotherapy for palliation of debilitating malignant ascites. Eur J Surg Oncol. 2006;32:682-685.